• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

    3/27/26 7:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value

    Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders

    Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed

    Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiving interest from multiple credible parties. The letter also urges the Board to immediately take a more constructive and responsible approach to evaluating strategic alternatives.

    March 27, 2026

    Teleflex Incorporated

    550 E. Swedesford Road

    Suite 400

    Wayne, PA 19087

    Members of the Board of Directors:

    We are writing to you on behalf of funds managed by Irenic Capital Management L.P. (together with such funds, "Irenic" or "we"). Irenic is one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") with 2% ownership.

    We are writing to you following our conversation with Dr. Stephen Klasko, Chairman of the Board of Directors (the "Board"), last week, during which Dr. Klasko indicated that the Board has directed the Company's advisors to refuse approaches from potential acquirors of Teleflex. He made clear to us that, in his view, it did not make sense to even have a conversation with interested parties at this point – regardless of how much such parties might be willing to pay for Teleflex. As we conveyed on the call and in our subsequent private communication with the Board, we firmly believe that posture is unreasonable and irresponsible.

    Over the past five years, Teleflex has delivered a total shareholder return of negative 73% – a level of sustained value destruction that demands, at a minimum, openness to evaluating credible opportunities to maximize shareholder value. At the same time, the Company is operating without a permanent Chief Executive Officer because the Board failed at its primary job – properly planning for succession.

    Total Shareholder Returns Assuming Dividends are Reinvested in Security
    Data as of 03/20/2026 Time Period
    1Y 3Y 5Y 10Y
    Teleflex Incorporated

    (24 %)

    (54 %)

    (73 %)

    (25 %)

     

     

     

     

    Benchmark Performance

     

     

     

     

    S&P 500

    16 %

    72 %

    79 %

    276 %

    S&P 500 Healthcare Index

    1 %

    20 %

    37 %

    159 %

    S&P 500 Healthcare Equipment Index

    (10 %)

    13 %

    8 %

    164 %

    iShares U.S. Medical Devices ETF

    (9 %)

    6 %

    3 %

    183 %

    Average of Proxy Peers [1]

    (2 %)

    (8 %)

    (15 %)

    183 %

     

     

     

     

    Teleflex's Relative Performance vs. Benchmark

     

     

     

     

    S&P 500

    (40 %)

    (126 %)

    (151 %)

    (301 %)

    S&P 500 Healthcare Index

    (24 %)

    (75 %)

    (110 %)

    (184 %)

    S&P 500 Healthcare Equipment Index

    (14 %)

    (67 %)

    (81 %)

    (189 %)

    iShares U.S. Medical Devices ETF

    (15 %)

    (60 %)

    (76 %)

    (208 %)

    Average of Proxy Peers [1]

    (22 %)

    (46 %)

    (57 %)

    (208 %)

     
    [1] Executive Compensation Peer Group as per Teleflex's 2025 Proxy Statement, excluding NuVasive, Inc., which is no longer a standalone publicly listed company.
     
    Source: Bloomberg

    The current Board, which is comprised of long-tenured directors, has presided over a sustained period of value destruction. Remarkably, one would think, having decided that the Company is so undervalued that the Board will not even entertain conversations about selling the Company, that members of the Board would be buying stock hand over fist. However, as far as we can tell, Dr. Klasko, in his eighteen years on the Board, has not bought a single share (!!) and neither has Candace Duncan nor Neena Patil. In fact, this Board, collectively tenured nearly eighty years, has purchased a grand total of 8,250 shares of Teleflex on the open market. Were the Board collectively a single shareholder, it would be the 223rd largest shareholder on the Bloomberg holders list based on these open market purchases.

    Open Market Purchases & Sales by Teleflex Board of Directors
    Director Date Appointed

    to Board
    Days Since

    Joining Board
    Days Since Last Open

    Market Purchase
    Total Shares Purchased

    in Open Market
    Total Shares Sold

    in Open Market
    Stephen K. Klasko (Chairman)

    May 5, 2008

    6,535

    No Open Market Purchases

    0

    14,364

    Stuart A. Randle (Interim CEO)

    May 1, 2009

    6,174

    234

    1,000

    24,760

    Candace H. Duncan

    May 1, 2015

    3,983

    No Open Market Purchases

    0

    0

    Gretchen R. Haggerty

    September 13, 2016

    3,482

    233

    1,500

    0

    Andrew A. Krakauer

    January 1, 2018

    3,007

    234

    3,000

    0

    John C. Heinmiller

    January 1, 2019

    2,642

    2,576

    1,250

    0

    Neena M. Patil

    April 29, 2022

    1,428

    No Open Market Purchases

    0

    0

    Jaewon Ryu

    May 5, 2023

    1,057

    234

    1,500

    0

     
    Source: Bloomberg, SEC Filings

    Based on our discussions with other significant shareholders, we believe our concerns are broadly shared. Against this backdrop, it is difficult to understand how the Board can justify refusing to engage with potential buyers. In its response to our communications, the Board asserted that it is making strategic decisions and conducting the search for a permanent CEO that it believes will best position the Company for shareholder value creation. Given its track record of value destruction and lack of alignment, we do not believe this Board has earned the right to unilaterally determine how value is best created on shareholders' behalf, and particularly not before it has thoroughly assessed all potential alternatives.

    In our view, Teleflex requires meaningful change at the Board level – most notably, a new Chair – as well as the engagement of independent advisors capable of supporting an objective evaluation of strategic alternatives. We are aware of multiple interested parties, and the Board's continued unwillingness to engage is not tenable. It is time – well past time – for the Board to take a more constructive and responsible approach and begin engaging with credible acquirors.

    Sincerely,

    Adam Katz

    Co-Founder, Chief Investment Officer

    Andy Dodge

    Co-Founder, Director of Research

    Akshay Amin

    Managing Director

    About Irenic

    Irenic Capital Management, LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260327185185/en/

    For Investors:

    Jeff Shookus

    Irenic Capital Management

    contact@irenicmgmt.com

    For Media:

    Longacre Square Partners

    irenic@longacresquare.com

    Get the next $TFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    5/8/2026$155.00Sector Perform → Outperform
    RBC Capital Mkts
    4/13/2026$135.00Underperform → Neutral
    BofA Securities
    3/27/2026$128.00Mkt Perform → Outperform
    Raymond James
    1/27/2026$138.00Hold → Buy
    Needham
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryu Jaewon was granted 1,090 shares, increasing direct ownership by 29% to 4,817 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    5/19/26 9:00:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A was granted 1,090 shares, increasing direct ownership by 15% to 8,309 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    5/19/26 8:59:25 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Haggerty Gretchen R was granted 1,090 shares, increasing direct ownership by 17% to 7,395 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    5/19/26 8:58:58 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Teleflex from Sector Perform to Outperform and set a new price target of $155.00

    5/8/26 8:43:10 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex upgraded by BofA Securities with a new price target

    BofA Securities upgraded Teleflex from Underperform to Neutral and set a new price target of $135.00

    4/13/26 9:17:17 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex upgraded by Raymond James with a new price target

    Raymond James upgraded Teleflex from Mkt Perform to Outperform and set a new price target of $128.00

    3/27/26 8:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    SEC Filings

    View All

    Teleflex Incorporated filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - TELEFLEX INC (0000096943) (Filer)

    6/1/26 7:59:04 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Teleflex Incorporated

    SD - TELEFLEX INC (0000096943) (Filer)

    5/28/26 2:22:09 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - TELEFLEX INC (0000096943) (Filer)

    5/27/26 5:23:02 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

    Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the "Notes") at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes").

    6/1/26 5:40:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032

    Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the "Notes"), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes"). The offering of t

    6/1/26 7:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer

    First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™1 Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer2 Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innova

    5/21/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Teleflex Announces Quarterly Dividend

    Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believ

    5/15/26 4:30:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

    Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro for

    5/7/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces First Quarter 2026 Earnings Conference Call Information

    Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 a.m. Eastern Time on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

    4/23/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    Teleflex Appoints Jason Weidman as President and CEO

    Proven Industry Leader to Guide Company's Next Chapter of Growth and Value Creation Teleflex Incorporated (NYSE:TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex's Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO. Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc

    4/30/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Governance Updates

    Michael J. Tokich, Medical Technology Industry Veteran, Nominated as Independent Director; Andrew A. Krakauer Appointed Chairman of the Board Effective Following 2026 Annual Meeting Board to Establish Growth and Operating Committee Company to Commence Share Repurchases Ahead of Schedule Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company's previously announced program ahead of schedule. The an

    4/9/26 6:30:00 AM ET
    $MTD
    $STE
    $TFX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Specialties
    Health Care

    Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution

    Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.

    3/27/26 12:57:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care